Integrated Investment Consultants, LLC Alkermes Plc. Transaction History

Integrated Investment Consultants, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 18, 2023	BUY	$25.31 - $29.02 $233,611 - $267,854	9,230 New	9,230 $260,000
Q4 2022 Feb 13, 2023	SELL	$21.94 - $26.24 $438 - $524	-20 Reduced 0.19%	10,400 $271,000
Q3 2022 Nov 21, 2022	BUY	$22.0 - $31.87 $12,320 - $17,847	560 Added 5.68%	10,420 $233,000
Q2 2022 Jul 19, 2022	SELL	$26.4 - $30.54 $17,160 - $19,851	-650 Reduced 6.18%	9,860 $293,000
Q1 2022 May 16, 2022	SELL	$23.07 - $27.99 $32,759 - $39,745	-1,420 Reduced 11.9%	10,510 $277,000
Q4 2021 Jan 10, 2022	BUY	$21.47 - $32.08 $72,998 - $109,072	3,400 Added 39.86%	11,930 $278,000
Q3 2021 Oct 28, 2021	BUY	$23.37 - $32.13 $199,346 - $274,068	8,530 New	8,530 $263,000

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.88B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Integrated Investment Consultants, LLC, based on Form 13F filings with the SEC.

Stay updated on Integrated Investment Consultants, LLC with notifications on news.